National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 23 of 41
Elderly Influenza Vaccine Immunogenicity Substudy
NCT00170482
Vaccine Treatment for HIV-Infection
NCT00108654
Experimental Vaccine for Malaria
NCT00114010
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
NCT00119379
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
NCT00076232
Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs
NCT00099671
Tuberculosis Immunity in Children
NCT00170638
Eldery High Dose TIV 2005
NCT00115531
Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
NCT00119405
Vaccine to Prevent West Nile Virus Disease
NCT00106769
Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS
NCT00106795
Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)
NCT00340574
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
NCT00295581
Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults
NCT00133471
Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment
NCT00105417
Effects of Anti-HIV Therapy on Nervous System Function
NCT00432003
A/H5N1in Adult - Aventis
NCT00115986
Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial
NCT00100386
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
NCT00239733
Urban Environmental Factors and Childhood Asthma
NCT00114881
A Study of Anal Cancer Development in HIV Infected People
NCT00107679
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults
NCT00094718
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
NCT00074581
Clinical and Immunological Evaluation of Children With Allergies
NCT00102570
HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers
NCT00102089
Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients
NCT00101374
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
NCT00240994
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults
NCT00094705
Collection of Blood Samples From HIV Infected People
NCT00096772
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
NCT00104299
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
NCT00074425
Phase I Study of a Vaccine for Severe Acute Respiratory Syndrome (SARS)
NCT00099463
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
NCT00340691
Fluarix Immunogenicity and Safety Trial
NCT00100399
Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People
NCT00100633
Influenza Vaccine in Pediatric Transplant Subjects
NCT00133510
Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients
NCT00089466
FLU-VACS Comparative Study in Adults
NCT00133523
Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age
NCT00231920
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
NCT00095316
Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant
NCT00092937
Genetic Risk Factors for Severe Asthma
NCT00090740
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
NCT00094380
Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults
NCT00083603
RSV Challenge in Healthy Adults
NCT00100373
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults
NCT00089908
Acute Viral Respiratory Infections in Elderly
NCT00170495
Candidate HIV Vaccine
NCT00089531
New Challenge Pool of Norwalk Virus Inoculum
NCT00138476
Evaluation of an Asthma Treatment Strategy Based on Exhaled Nitric Oxide Measurements in Adolescents
NCT00114413
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.